Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21752525 | 0.82 | LMNA (0.45) | LMNATSHRNPSR1MEN1KMT2A | |
| SCHEMBL24878009 | 0.81 | STAT3 (0.40) | LMNATSHRNPSR1MEN1KMT2A | |
| SCHEMBL25097670 | 0.79 | LMNA (0.60) | LMNATSHRNPSR1MEN1KMT2A | |
| SCHEMBL24877850 | 0.77 | LMNA (0.51) | LMNATSHRNPSR1GAATDP1 | |
| SCHEMBL21752581 | 0.75 | LMNA (0.49) | LMNATSHRNPSR1HPGDTDP1 | |
| SCHEMBL21995741 | 0.73 | MAPT (0.54) | LMNATSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL31011269 | 0.73 | MAPT (0.54) | LMNATSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL27381184 | 0.73 | SIGMAR1 (0.58) | LMNATSHRNPSR1KMT2AHPGD | |
| SCHEMBL17024880 | 0.72 | LMNA (0.52) | LMNATSHRNPSR1MEN1KMT2A | |
| SCHEMBL22053931 | 0.72 | LMNA (0.55) | LMNATSHRNPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264134-B2 | Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-04-01 | — | — | US | disclosed |
| EP-3886845-B1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3886845-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020112581-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | LMNA 4773/4885TSHR 3557/4885NPSR1 1010/4885 |
| US-12264134-B2 | Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, AADAC | LMNA 4655/4885TSHR 3608/4885NPSR1 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.